Contrast agent may be linked to nephrogenic fibrosis
Gadolinium-containing contrast agents used at high doses may be linked to development of nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD) that occurs in patients with kidney failure. The FDA has learned of 25 cases of NSF/NFD in patients who received Omniscan, a gadolinium contrast agent, and then underwent a magnetic resonance angiography (MRA).
Contrast agent may be linked to nephrogenic fibrosis
Gadolinium-containing contrast agents used at high doses may be linked to development of nephrogenic systemic fibrosis or nephrogenic fibrosing dermopathy (NSF/NFD) that occurs in patients with kidney failure. The FDA has learned of 25 cases of NSF/NFD in patients who received Omniscan, a gadolinium contrast agent, and then underwent a magnetic resonance angiography (MRA). The agency said it will continue to research the possible link and investigate whether additional patients have had a similar experience. The FDA urges healthcare providers and patients to report any such events to http://www.fda.gov/medwatch/report.htm or by phone to (1)-800 FDA-1088.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.
